HRTS

Tema GLP-1 Obesity & Cardiometabolic ETF · NAS

Category Health Care
Expense Ratio 0.75%
Listing Date Nov 21, 2023
Volume 6,290.0
Market Cap (AUM) $84.15M

Performance

+0.3%

-2.16%

-1.08%

+10.16%

+10.85%

YTD

+27.44%

Top Holdings

Name
Symbol
%Assets
Vertex Pharmaceuticals IncorporatedVRTX6.18%
Eli Lilly and CompanyLLY5.71%
Amgen Inc.AMGN5.48%
Novo Nordisk A/S Class BNOVO.B5.25%
DexCom, Inc.DXCM3.84%
Cytokinetics, IncorporatedCYTK3.56%
Insulet CorporationPODD3.30%
Mereo BioPharma Group plc Sponsored ADRMREO3.24%
Edwards Lifesciences CorporationEW3.16%
BridgeBio Pharma, Inc.BBIO2.96%

Advanced Technical Analysis

Technical Analysis of HRTS 2024-10-21

The Moving Average Score of 63 indicates a bullish sentiment, while the Oscillators Score of 43 and the Technical Score of 53 suggest a more neutral outlook. Overall, the combined scores reflect a mixed sentiment, with a stronger bullish indication from the moving averages tempered by neutral signals from the other indicators.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Recent News & Updates

2024-04-21 23:10
10 Best Performing Biotech ETFs in 2024(Insidermonkey)
2024-03-13 12:40
'Continued innovation' is key when investing in weight loss trend(Yahoo Finance Video)

Page 1 of 1

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.